Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presenter: Jennifer R. Brown

The choice of therapy for chronic lymphocytic leukemia (newly diagnosed as well as relapsed/refractory disease) depends on the disease (presence or absence of del(17p) or TP53 mutation) and patient characteristics (age, comorbidities, functional status and patient preference). Many patients can choose between continuous treatment with a Bruton’s tyrosine kinase (BTK) inhibitor or time-limited therapy with venetoclax/obinutuzumab. For patients with 17p deletions, the data support the use of continuous treatment with a BTK inhibitor, although these patients should also be referred to clinical trials evaluating novel combination therapy options with minimal residual disease monitoring. The choice of therapy for relapsed disease also depends on prior therapy and duration of response to prior therapy in addition to the disease and patient characteristics (as mentioned earlier). BTK inhibitor– or venetoclax-based regimens are recommended for patients experiencing relapse following chemoimmunotherapy. In the case of disease relapse following BTK inhibitor therapy, prospective data are available only for venetoclax-based regimens, whereas disease relapse (after a period of durable remission) following time-limited therapy with venetoclax-based regimens can be managed through re-treatment with venetoclax or a BTK inhibitor.

Disclosures: Dr. Brown has disclosed receiving consulting fees from AbbVie, Inc., Acerta/Astra-Zeneca, BeiGene, Bristol-Myers Squibb/Juno/Celgene, Catapult, Eli Lilly and Company, Genentech/Roche, Janssen Pharmaceutica Products, LP, MEI Pharma Inc., MorphoSys AG, Nextcea, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Rigel; grant/research support from Gilead Sciences, Inc., Loxo/Lilly, SecuraBio, Sun, and TG Therapeutics; and other financial benefit from Invectys.

Correspondence: Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115. Email: jbrown2@partners.org
  • 1.

    Brown JR, Robak T, Ghia P, et al. Efficacy and safety of zanubrutinib in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): follow-up results from arm C of the SEQUOIA (BGB-3111-304) trial. Blood 2020;136(Suppl 1):1112.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379:25172528.

  • 3.

    Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381:432443.

  • 4.

    Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet 2020;395:12781291.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet 2020;21:11881200.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 2019;94:13531363.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2020;38:28492861.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial [published online July 26, 2021]. J Clin Oncol 10.1200/JCO.21.01210

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Kater AP, Kipps TJ, Eichhorst B, et al. Five-year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (Pts) following fixed-duration venetoclax-rituximab (VenR) therapy (Tx) [abstract]. Presented at the 62nd ASH Annual Meeting and Exposition; December 5–8, 2020. Abstract 125.

    • Search Google Scholar
    • Export Citation
  • 10.

    Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018;19:6575.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Lin VS, Lew TE, Handunnetti SM, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood 2020;135:22662270.

  • 12.

    Buckley SA, Appelbaum FR, Walter RB. Prognostic and therapeutic implication of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant 2013;48:630641.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol 2019;37:27222729.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Kater A, Owen C, Moreno C, et al. Fixed duration ibrutinib and venetoclax versus chlorambucil plus obinutuzumab for first-line chronic lymphocytic leukemia: primary analysis of the phase 3 GLOW study [abstract]. Presented at the European Hematology Association 2021 Virtual Congress; June 12, 2021. Abstract LB1902.

    • Search Google Scholar
    • Export Citation
  • 15.

    Rogers KA, Huang Y, Ruppert AS, et al. Three-year follow-up from a phase 2 study of combination obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia. Blood 2020;136(Suppl 1):910.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 353 353 353
PDF Downloads 178 178 178
EPUB Downloads 0 0 0